Oxford Immunotec Global PLC (OXFD) financial statements (2021 and earlier)

Company profile

Business Address 94C INNOVATION DRIVE
ABINGDON, OX14 4RZ
State of Incorp.
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18119390598450
Cash and cash equivalents18119390598450
Restricted cash and investments     0
Receivables1814171377
Inventory, net of allowances, customer advances and progress billings11810776
Inventory11810776
Contract with customer, asset2 
Other undisclosed current assets433243
Total current assets:2162171208210166
Noncurrent Assets
Operating lease, right-of-use asset7
Property, plant and equipment779865
Intangible assets, net (including goodwill)33121500
Goodwill224400
Intangible assets, net (excluding goodwill)0081100
Restricted cash and investments000000
Deferred income tax assets2
Other noncurrent assets  0300
Deferred tax assets, net12   
Other undisclosed noncurrent assets 5 1622
Total noncurrent assets:1915244287
TOTAL ASSETS:23523214412411074
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities131418171413
Accounts payable237342
Accrued liabilities10111114107
Employee-related liabilities     3
Deferred revenue0
Debt100000
Business combination, contingent consideration, liability   1  
Deferred revenue and credits0022
Other undisclosed current liabilities 44  (3)
Total current liabilities:141822181512
Noncurrent Liabilities
Long-term debt and lease obligation80303000
Long-term debt, excluding current maturities00303000
Operating lease, liability8
Liabilities, other than long-term debt  0311
Other liabilities  00  
Business combination, contingent consideration, liability   311
Other undisclosed noncurrent liabilities  4   
Total noncurrent liabilities:80343322
Total liabilities:221857511713
Stockholders' equity
Stockholders' equity attributable to parent21421488739361
Common stock000000
Additional paid in capital305303295249244187
Accumulated other comprehensive loss(7)(9)(6)(8)(5)(5)
Accumulated deficit(84)(81)(202)(169)(146)(122)
Total stockholders' equity:21421488739361
TOTAL LIABILITIES AND EQUITY:23523214412411074

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues7460103866350
Revenue, net103866350
Cost of revenue(19)(17)(47)(39)(30)(24)
Cost of goods and services sold(19)(17)(47)(39)(30)(24)
Gross profit:544356473325
Operating expenses(61)(64)(110)(73)(57)(47)
Operating loss:(6)(21)(54)(26)(24)(22)
Nonoperating income (expense)(2)(0)(2)1(0)(0)
Foreign currency transaction gain (loss), before tax(2)0(2)1(0)(0)
Other nonoperating income (expense)0(0)(0)(1)00
Interest and debt expense (2)    
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes4(2)24(1)(0) 
Loss from continuing operations before equity method investments, income taxes:(4)(25)(31)(26)(24)(22)
Other undisclosed loss from continuing operations before income taxes     (0)
Loss from continuing operations before income taxes:(4)(25)(31)(26)(24)(22)
Income tax expense (benefit)237(2)4(0)(0)
Income (loss) from continuing operations:(1)13(33)(22)(24)(22)
Income (loss) from discontinued operations(0)108    
Net income (loss) available to common stockholders, diluted:(2)121(33)(22)(24)(22)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(2)121(33)(22)(24)(22)
Other comprehensive loss(0)  (2)(1)(1)
Comprehensive income (loss):(2)121(33)(25)(25)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(3)2   
Comprehensive income (loss), net of tax, attributable to parent:(1)118(31)(25)(25)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: